ACG eBook
ACG IBS 2022.indd
Read More
Author: Rebecca Shover
Factors Associated With Improved COVID-19 Outcomes for CLL
Patients with chronic lymphocytic leukemia (CLL) infected with COVID-19 during the most recent...
Read More
Test Your ACR Knowledge!
The ACR 2022 PhysQuiz was created by the editorial staff at Physician’s Weekly.
Read More
Butter is OK
“The good news, it’s OK to eat butter after all. The bad news, it’s not OK to...
Read More
Baseline CTC Count Can Guide First-Line Treatment in HR-Positive/HER-Negative Metastatic Breast Cancer
A single assessment of the circulating tumor cells (CTC) count before treatment can guide the...
Read More
Resistance to CDK4/6 Inhibitors Likely Due to Expansion of Pre-Existing Resistant Clones
In vitro studies using DNA barcoded cell lines demonstrated that resistance to CDK4/6 inhibitors...
Read More
No Benefit of Palbociclib With Fulvestrant Beyond Progression on Prior CDK4/6 Inhibition
Among patients with HR-positive/HER2-negative metastatic breast cancer, combining palbociclib with...
Read More
Improved Benefit of Elacestrant With Longer Duration of CDK4/6 Inhibition
Duration of first-line CDK4/6 inhibitor therapy in patients with ER-positive/HER2-negative...
Read More
T-DXd Superior Vs Chemotherapy-Based Treatments When Previously Treated With T-DM1
Compared with capecitabine-based regimens, trastuzumab deruxtecan (T-DXd) led to higher response...
Read More
Germline Pathogenic Variants for Breast Cancer Also Increase Contralateral Breast Cancer Risk
In women carrying a germline pathogenic variant for breast cancer, like BRCA1, BRCA2, or CHEK2,...
Read More
Anti-PD-1/Anti-LAG-3 Combination Highly Effective in HER2-Negative Breast Cancer
Paclitaxel/cemiplimab/fianlimab is a highly effective combination for neoadjuvant therapy in both...
Read More
Endocrine Interruption Does Not Impact Short-Term Disease in Breast Cancer
Patients with breast cancer who pause their endocrine therapy to try to get pregnant experienced...
Read More
MammaPrint Predicts Extended Endocrine Therapy Benefit
In addition to predicting the benefit of adjuvant chemotherapy in patients with early breast...
Read More
Dr. MedLaw Q&A: Patient Abandonment After Being Fired?
Q: I was just fired from my pulmonology group after a very bad fallout with the managing partner....
Read More
MagnetisMM-3 Trial: Elranatamab Promising for MM
Elranatamab displayed a manageable safety profile in patients with relapsed/refractory multiple...
Read More
MRD by qPCR Prognostic of Outcomes in Venetoclax-Treated, NPM1-Mutated AML
Measurable/minimal residual disease (MRD) assessment by qPCR was strongly associated with clinical...
Read More
Excellent Results for Triplet Regimen in FLT3-Mutated AML
The triplet combination of azacitidine, venetoclax, and gilteritinib induced high response rates...
Read More
CAR-Hematotox Score Predicts Toxicity, Infection & Clinical Outcomes in MCL
Patients with relapsed or refractory mantle cell lymphoma (MCL) and a high CAR-hematotox score had...
Read More
Deep & Durable Responses for Quadruple Therapy in Smouldering MM
The quadruple therapy of daratumumab, carfilzomib, lenalidomide, and dexamethasone was well...
Read More